Last 37 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.24 | 10.15 | 4.27 | 4.26 | 1.46 | 2.52 | 1.89 | 2.10 | 2.26 | 1.46 | 1.34 | 1.33 | 2.45 | 3.00 | 1.80 | 2.64 | 2.46 | 2.31 | 1.95 | 3.24 | 3.37 |
| — | +302.0% | +126.2% | +103.0% | -35.2% | +72.9% | +41.0% | +57.3% | -7.8% | -51.3% | -25.7% | -49.6% | -0.6% | +29.8% | -7.8% | -18.4% | -27.0% | -44.5% | -31.4% | -11.2% | -12.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -107.9% | -51.3% | -38.9% | -29.9% | -27.7% | -23.0% | -16.5% | -15.4% | -13.1% | -13.4% | -13.8% | -11.5% | -12.3% | -9.3% | -8.6% | -8.1% | -10.9% | -10.3% | -7.5% | -6.6% | -6.3% |
| — | -122.8% | -135.5% | -94.9% | -110.9% | -71.6% | -19.3% | -33.2% | -7.1% | -44.9% | -61.7% | -42.3% | -13.0% | +9.9% | -14.6% | -22.2% | -73.1% | -84.1% | -76.3% | -18.4% | +15.9% | |
| ROA | -71.0% | -23.9% | -22.0% | -19.6% | -19.3% | -17.0% | -12.8% | -12.0% | -10.3% | -10.5% | -10.8% | -9.3% | -10.3% | -7.9% | -7.4% | -7.1% | -9.6% | -9.2% | -6.7% | -6.0% | -5.7% |
| — | -40.5% | -71.3% | -62.9% | -88.4% | -61.5% | -18.9% | -29.0% | +0.3% | -32.7% | -45.2% | -31.1% | -7.0% | +13.7% | -11.0% | -18.6% | -68.4% | -79.3% | -71.7% | -20.3% | +8.4% | |
| ROIC | -106.7% | -101.4% | -47.3% | -26.9% | -22.9% | -19.5% | -15.6% | -13.6% | -12.7% | -11.8% | -11.4% | -10.0% | -10.4% | -8.9% | -8.7% | -8.0% | -9.5% | -9.2% | -7.1% | -6.7% | -6.7% |
| — | -420.6% | -202.7% | -98.1% | -79.8% | -64.4% | -37.5% | -35.8% | -22.0% | -33.0% | -31.3% | -24.1% | -10.0% | +2.9% | -22.0% | -20.7% | -40.5% | -49.4% | -22.5% | -6.6% | -9.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 1.06 | 0.67 | 0.36 | 0.29 | 0.23 | 0.18 | 0.16 | 0.20 | 0.18 | 0.20 | 0.18 | 0.13 | 0.12 | 0.11 | 0.10 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 |
| — | +367.6% | +266.7% | +130.0% | +45.2% | +27.3% | -9.6% | -12.3% | +52.8% | +50.5% | +85.1% | +77.3% | +56.3% | +49.6% | +37.0% | +34.1% | +16.1% | +14.4% | +19.7% | +16.8% | -56.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.79 | 5.23 | 4.79 | 5.60 | 6.31 | 6.94 | 7.95 | 11.43 | 10.11 | 13.46 | 10.72 | 12.40 | 12.76 | 17.06 | 17.52 | 23.58 | 16.12 | 19.79 | 19.46 | 23.39 | 26.71 |
| — | -24.7% | -39.7% | -51.0% | -37.6% | -48.4% | -25.9% | -7.8% | -20.8% | -21.1% | -38.8% | -47.4% | -20.9% | -13.8% | -10.0% | +0.8% | -39.7% | -35.9% | -41.5% | -39.0% | +37.2% | |
| Quick Ratio | 4.79 | 5.23 | 4.79 | 5.60 | 6.31 | 6.94 | 7.95 | 11.43 | 10.11 | 13.46 | 10.72 | 12.40 | 12.76 | 17.06 | 17.52 | 23.58 | 16.12 | 19.79 | 19.46 | 23.39 | 26.71 |
| — | -24.7% | -39.7% | -51.0% | -37.6% | -48.4% | -25.9% | -7.8% | -20.8% | -21.1% | -38.8% | -47.4% | -20.9% | -13.8% | -10.0% | +0.8% | -39.7% | -35.9% | -41.5% | -39.0% | +37.2% | |
| Interest Coverage | -34.50 | -25.83 | -16.56 | -35.15 | -159.42 | -45.09 | -36.68 | -33.19 | -29.71 | -29.05 | -29.77 | -36.16 | -42.34 | -33.31 | -33.21 | -27.55 | -77.37 | -75.55 | -56.17 | -52.47 | -51.70 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 37 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying REPL stock.
Replimune Group, Inc.'s current P/E is -3.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Replimune Group, Inc.'s business trajectory between earnings reports.